Enanta Pharmaceuticals Stock (NASDAQ:ENTA)
Previous Close
$5.32
52W Range
$4.71 - $17.60
50D Avg
$6.38
200D Avg
$9.77
Market Cap
$113.06M
Avg Vol (3M)
$429.55K
Beta
0.48
Div Yield
-
ENTA Company Profile
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.